133 related articles for article (PubMed ID: 35118468)
1. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Toledo EG; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RK; Rannard S; Stewart J; Owen A
bioRxiv; 2023 Mar; ():. PubMed ID: 35118468
[TBL] [Abstract][Full Text] [Related]
2. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice.
He Y; Henley J; Sell P; Comai L
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760
[TBL] [Abstract][Full Text] [Related]
3. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
4. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
6. The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
bioRxiv; 2022 Jun; ():. PubMed ID: 35734088
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice.
Toomer G; Burns W; Garcia L; Henry G; Biancofiori A; George A; Duffy C; Chu J; Sides M; Muñoz M; Garcia K; Nikolai-Yogerst A; Peng X; Westfall L; Baker R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423193
[TBL] [Abstract][Full Text] [Related]
8. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
9. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
[TBL] [Abstract][Full Text] [Related]
10. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
11. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
12. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Pathogenicity of SARS-CoV-2 Delta and Omicron Variants by Analyzing the Expression Patterns of Immune Response Genes in K18-hACE2 Transgenic Mice.
Kuruppuarachchi KAPP; Jang Y; Seo SH
Front Biosci (Landmark Ed); 2022 Nov; 27(11):316. PubMed ID: 36472114
[TBL] [Abstract][Full Text] [Related]
14. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y
Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462
[TBL] [Abstract][Full Text] [Related]
15. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
[TBL] [Abstract][Full Text] [Related]
17. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB; Mackin S; Errico JM; Chong Z; Madden EA; Whitener B; Guarino B; Schmid MA; Rosenthal K; Ren K; Dang HV; Snell G; Jung A; Droit L; Handley SA; Halfmann PJ; Kawaoka Y; Crowe JE; Fremont DH; Virgin HW; Loo YM; Esser MT; Purcell LA; Corti D; Diamond MS
Nat Commun; 2022 Jul; 13(1):3824. PubMed ID: 35780162
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters.
Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani H; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
bioRxiv; 2023 May; ():. PubMed ID: 37205409
[TBL] [Abstract][Full Text] [Related]
19. Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.
Singh G; Warang P; García-Bernalt Diego J; Chang L; Bykov Y; Singh S; Pache L; Cuadrado-Castano S; Webb B; Garcia-Sastre A; Schotsaert M
Res Sq; 2023 Nov; ():. PubMed ID: 38077015
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice.
Tarrés-Freixas F; Trinité B; Pons-Grífols A; Romero-Durana M; Riveira-Muñoz E; Ávila-Nieto C; Pérez M; Garcia-Vidal E; Perez-Zsolt D; Muñoz-Basagoiti J; Raïch-Regué D; Izquierdo-Useros N; Andrés C; Antón A; Pumarola T; Blanco I; Noguera-Julián M; Guallar V; Lepore R; Valencia A; Urrea V; Vergara-Alert J; Clotet B; Ballana E; Carrillo J; Segalés J; Blanco J
Front Microbiol; 2022; 13():840757. PubMed ID: 35602059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
